Adagio Therapeutics, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Commercial Services » Miscellaneous Commercial Services
ETSYEtsy, Inc. 0.00%148.857.5%$381.91m
EFXEquifax, Inc. 2.03%230.242.0%$212.83m
CRLCharles River Laboratories International, Inc. -1.81%318.784.5%$134.57m
FLTFLEETCOR Technologies, Inc. -2.81%220.063.7%$111.50m
CPRTCopart, Inc. -0.48%126.084.4%$106.02m
CHGGChegg, Inc. -1.49%25.8213.1%$85.94m
CLVTClarivate Plc -3.48%15.820.0%$75.94m
TAXLiberty Tax, Inc. Class A 2.43%47.262.5%$64.43m
BAHBooz Allen Hamilton Holding Corp. -0.42%85.012.1%$55.44m
FOURShift4 Payments, Inc. -0.78%46.070.0%$53.39m
BFAMBright Horizons Family Solutions, Inc. 0.17%126.491.4%$48.46m
CNXCConcentrix Corp. 0.05%169.920.1%$48.43m
PAGSPagSeguro Digital Ltd. -0.10%20.720.0%$47.74m
TASKTaskUs, Inc. -2.71%28.010.0%$43.71m
SYNHSyneos Health, Inc. -0.82%85.530.0%$41.66m

Company Profile

Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren? Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.